Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Bacitracin→

Bacitracin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1405-87-4
Molecular formula
C66H103N17O16S
Molecular weight
1422.7 g/mol
Drug class
Polypeptide antibiotictopical antibacterial agent
Mechanism of action
Inhibits bacterial cell-wall synthesis by preventing dephosphorylation and recycling of bactoprenol (undecaprenyl pyrophosphate), a lipid carrier required for transport of peptidoglycan precursors across the bacterial membrane.
Indications / reported uses
  • Topical treatment or prevention of infection in minor superficial skin wounds in authorised topical products
  • Ophthalmic formulations are used for selected superficial bacterial eye infections; route and combination product determine the indication. Topical and systemic uses are not interchangeable.

Sources: US DailyMed — Bacitracin topical products · NLM MeSH — Bacitracin · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Bacitracin Environmental Risk Assessment (ERA) (the Bacitracin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.